The Growth/Differentiation Factor 15 pipeline drugs market research report outlays comprehensive information on the Growth/Differentiation Factor 15 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Growth/Differentiation Factor 15 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Metabolic Disorders, Women’s Health, and Immunology which include the indications Cancer Anorexia-Cachexia Syndrome, Solid Tumor, Obesity, Hyperemesis Gravidarum, and Autoimmune Disorders. It also reviews key players involved in Growth/Differentiation Factor 15 targeted therapeutics development with respective active and dormant or discontinued products.
The Growth/Differentiation Factor 15 pipeline targets constitutes close to 14 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 3, 4, and 5 respectively.
Growth/Differentiation Factor 15 overview
Growth/differentiation factor 15 (GDF15) is a protein that in humans is encoded by the GDF15 gene. This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression.
For a complete picture of Growth/Differentiation Factor 15’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
